Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the fibromyalgia drug market will undergo significant growth with the anticipated launch of milnacipran, the first drug to be specifically indicated for the disease. The new Pharmacor study entitled Fibromyalgia finds that milnacipran, given its higher price point, promising efficacy, and first-to-market status, will have a major impact on the growth of a market currently dominated by older, more inexpensive drugs.

The study also found that along with milnacipran, duloxetine will drive the drug market for fibromyalgia therapies from 2002 to 2012. Duloxetine will launch for other indications in the United States and Europe in 2004 and in Japan in 2006, and will see significant off-label use for treating fibromyalgia, according to physician experts interviewed by Decision Resources.

"Both milnacipran and duloxetine will garner significant patient share and will drive growth in the market because they will be expensive relative to most current fibromyalgia therapies," said Stephen Ames, analyst at Decision Resources. "Sales of duloxetine and milnacipran will total approximately $127 million in 2012 and account for more than 25% of the overall fibromyalgia market."

About Fibromyalgia

Fibromyalgia is a relatively common chronic pain syndrome of unknown etiology affecting more that 2% of the general population in the major pharmaceutical markets. Experts agree that significant unmet need exists at virtually every step of fibromyalgia research and management. Moreover, awareness of the syndrome among primary care physicians and patients remains low.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Fibromyalgia is a Mosaic study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Sales For Crohn's Disease Drug Therapies Will Nearly Double From $713 Million In 2002 To $1.2 Billion In 2012

View Now